186 related articles for article (PubMed ID: 15125753)
1. Efavirenz-associated gynecomastia: report of five cases and review of the literature.
Jover F; Cuadrado JM; Roig P; Rodríguez M; Andreu L; Merino J
Breast J; 2004; 10(3):244-6. PubMed ID: 15125753
[TBL] [Abstract][Full Text] [Related]
2. A case-control study of gynecomastia in HIV-1-infected patients receiving HAART.
Rahim S; Ortiz O; Maslow M; Holzman R
AIDS Read; 2004 Jan; 14(1):23-4, 29-32, 35-40. PubMed ID: 14959701
[TBL] [Abstract][Full Text] [Related]
3. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz.
Caso JA; Prieto Jde M; Casas E; Sanz J
AIDS; 2001 Jul; 15(11):1447-8. PubMed ID: 11504970
[No Abstract] [Full Text] [Related]
4. Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment.
Mira JA; Lozano F; Santos J; Ramayo E; Terrón A; Palacios R; León EM; Márquez M; Macías J; Fernández-Palacin A; Gómez-Mateos J; Pineda JA;
Antivir Ther; 2004 Aug; 9(4):511-7. PubMed ID: 15456082
[TBL] [Abstract][Full Text] [Related]
5. Bilateral lipomastia in men: a side effect of highly active antiretroviral therapy.
Deonarain J; Ramdial PK; Singh B
Int J Surg Pathol; 2008 Apr; 16(2):171-5. PubMed ID: 18417674
[TBL] [Abstract][Full Text] [Related]
6. Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
Djabarouti S; Breilh D; Pellegrin I; Lavit M; Camou F; Caubet O; Fleury H; Saux MC; Pellegrin JL
J Antimicrob Chemother; 2006 Nov; 58(5):1090-3. PubMed ID: 16921181
[TBL] [Abstract][Full Text] [Related]
7. Does efavirenz cause breast enlargement?
TreatmentUpdate; 2001 Sep; 13(5):5-6. PubMed ID: 11768863
[No Abstract] [Full Text] [Related]
8. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
van Leth F; Lange JM
Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
[TBL] [Abstract][Full Text] [Related]
9. "Bullfrog neck," a unique morphologic trait in HIV lipodystrophy: case series and review of the literature.
Tierney EP; Hanke CW
Arch Dermatol; 2010 Nov; 146(11):1279-82. PubMed ID: 21079066
[TBL] [Abstract][Full Text] [Related]
10. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
Saka B; Akakpo AS; Bassowa A; Dapam AN; Mahamadou G; Teclessou JN; Mouhari-Toure A; Laouali AY; Mensah E; Kombaté K; Pitché P
Ann Dermatol Venereol; 2018 Dec; 145(12):773-776. PubMed ID: 30301570
[TBL] [Abstract][Full Text] [Related]
11. Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe.
Shawarira-Bote S; Shamu T; Chimbetete C
BMC Infect Dis; 2019 Aug; 19(1):715. PubMed ID: 31409277
[TBL] [Abstract][Full Text] [Related]
12. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
Kontorinis N; Dieterich DT
Semin Liver Dis; 2003 May; 23(2):173-82. PubMed ID: 12800070
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
Manosuthi W; Thongyen S; Chumpathat N; Muangchana K; Sungkanuparph S
HIV Med; 2006 Sep; 7(6):378-82. PubMed ID: 16903982
[TBL] [Abstract][Full Text] [Related]
15. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
Gutiérrez F; Navarro A; Padilla S; Antón R; Masiá M; Borrás J; Martín-Hidalgo A
Clin Infect Dis; 2005 Dec; 41(11):1648-53. PubMed ID: 16267739
[TBL] [Abstract][Full Text] [Related]
16. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.
Jemsek JG; Arathoon E; Arlotti M; Perez C; Sosa N; Pokrovskiy V; Thiry A; Soccodato M; Noor MA; Giordano M
Clin Infect Dis; 2006 Jan; 42(2):273-80. PubMed ID: 16355341
[TBL] [Abstract][Full Text] [Related]
17. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
Muñoz-Moreno JA; Fumaz CR; Ferrer MJ; González-García M; Moltó J; Negredo E; Clotet B
AIDS Rev; 2009; 11(2):103-9. PubMed ID: 19529750
[TBL] [Abstract][Full Text] [Related]
18. Another emerging event occurring during HIV infection treated with any antiretroviral therapy: frequency and role of gynecomastia.
Manfredi R; Calza L; Chiodo F
Infez Med; 2004 Mar; 12(1):51-9. PubMed ID: 15329529
[TBL] [Abstract][Full Text] [Related]
19. Efavirenz-associated breast hypertrophy in HIV-infection patients.
Mercié P; Viallard JF; Thiébaut R; Faure I; Rispal P; Leng B; Pellegrin JL
AIDS; 2001 Jan; 15(1):126-9. PubMed ID: 11192857
[No Abstract] [Full Text] [Related]
20. Haemolytic anaemia associated with efavirenz.
Freercks RJ; Mehta U; Stead DF; Meintjes GA
AIDS; 2006 May; 20(8):1212-3. PubMed ID: 16691081
[No Abstract] [Full Text] [Related]
[Next] [New Search]
